764.5500 -4.85 (-0.63%)
NSE Jan 23, 2026 15:31 PM
Volume: 22,832
 

764.55
-0.63%
Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharma has lost -25.01% in the last 6 Months
More from Alembic Pharmaceuticals Ltd.
Recommended